# Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)

Study · id `cardio:ct-nct01926782` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01926782](<https://clinicaltrials.gov/study/NCT01926782>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01926782

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 803 participants.

## Technical summary

Registry record NCT01926782. Randomized; quadruple masking; primary purpose treatment. Start 2013-09 (registry gives no type); primary completion 2014-09 (actual). Results posted on 2017-03-21.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 803 participants (enrolled count; ClinicalTrials.gov record NCT01926782, source copy `cardio:ctgov-nct01926782-2017-03-21`, retrieved 2026-10-31)
- Start date: 2013-09 (registry gives no type) (ClinicalTrials.gov record NCT01926782, source copy `cardio:ctgov-nct01926782-2017-03-21`, retrieved 2026-10-31)
- Primary completion: 2014-09 (actual) (ClinicalTrials.gov record NCT01926782, source copy `cardio:ctgov-nct01926782-2017-03-21`, retrieved 2026-10-31)
- Completion: 2015-04 (actual) (ClinicalTrials.gov record NCT01926782, source copy `cardio:ctgov-nct01926782-2017-03-21`, retrieved 2026-10-31)
- Results first posted: 2017-03-21 (ClinicalTrials.gov record NCT01926782, source copy `cardio:ctgov-nct01926782-2017-03-21`, retrieved 2026-10-31)
- Countries: United States; Bulgaria; Canada; Hungary; Israel; Norway; Slovakia; United Kingdom (ClinicalTrials.gov record NCT01926782, source copy `cardio:ctgov-nct01926782-2017-03-21`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01926782-2017-03-21`, retrieved 2026-10-31)

## The registry's words

- Brief title: Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)
- Condition: Hypercholesterolemia
- Intervention (Drug): Placebo (for alirocumab)
- Intervention (Drug): Alirocumab
- Intervention (Drug): Statin
- Lead sponsor: Regeneron Pharmaceuticals
- Lead sponsor class: INDUSTRY
- Collaborator: Sanofi
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry intervention name matches this record: Alirocumab (`cardio:alirocumab`)
- Registry lists this organization as the lead sponsor: Regeneron Pharmaceuticals (`cardio:org-regeneron-pharmaceuticals`)
- Registry lists this organization as a collaborator: Sanofi (`cardio:org-sanofi`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I (`cardio:pubmed-27639753`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in the ODYSSEY CHOICE I trial (`cardio:pubmed-32928709`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 4c5d7e8de6b8443b10c119143dd92348e171d7e86bfbababbe547f9cd8df5ba5
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
